spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Editorial

Jennifer Sadler-Venis

Advertising

David Hirsh   

 

 
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
THERAPEUTIC DEVELOPMENT
Therapeutic Transportation

Stay Cool


When transporting manufactured drugs, there are many factors that have the potential to damage product integrity. John Fink and Katheryn Shea at Brooks Life Science Systems explore best practices to avoid this with regards to cryopreservation.
Editors Letter
Editor’s Letter

Dr Deborah O’Neil, Editor of EBR, highlights the connections and debates that interlink the articles by our contributors this issue, with a particular focus on the protein problem and the need for tighter regulation across fields such as biomarkers and personalised medicine.
  CELL-BASED RESEARCH
Q&A: Genetic Modification

Express Yourself


We learn about the possibilities of cell engineering, genetic modification and protein production in this Q&A feature with the team at Oxford Genetics, who say that it could be possible to cure inherited diseases with new technology.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


 

Industry Events

PREP_2017

16-19 July 2017,

Advances in Separation Technologies: The PREP series of symposia is the most recognized international conference and exposition devoted to advances in separation technologies in the field of preparative and process chromatography. Join us at PREP 2017 for another dynamic and innovative program where experts from around the world will address the latest developments and hottest topics in all areas of preparative and process chromatography.
More info >>

 
News and Press Releases

Positive results from first preclinical in-vivo studies of Affimer therapeutics


More info >>

air transport logo

 

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement